Molecular diagnosis of infectious laryngotracheitis virus in laying hen farms located in Tungurahua, Ecuador

Avian infectious laryngotracheitis (ILT) is a disease caused by Gallid alphaherpesvirus 1 (GaHV-1), which is transmitted through respiratory secretions or fomites from infected birds, either naturally or through the use of chicken embryo-origin (CEO) live vaccines. The objective of this research was...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Revelo-Cueva, M., Vinueza-Burgos, C.V., Metz, G.E., Echeverría, M.G.
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional del Nordeste 2024
Materias:
Acceso en línea:https://revistas.unne.edu.ar/index.php/vet/article/view/7866
Aporte de:
Descripción
Sumario:Avian infectious laryngotracheitis (ILT) is a disease caused by Gallid alphaherpesvirus 1 (GaHV-1), which is transmitted through respiratory secretions or fomites from infected birds, either naturally or through the use of chicken embryo-origin (CEO) live vaccines. The objective of this research was to develop a molecular detection of GaHV-1 in laying hen farms located in Tungurahua Province. Laryngotracheal swabs and tracheal samples were collected from 47 farms. In addition, a recombinant vaccine with GaHV-1 glycoprotein B was used. Three farms tested positive to GaHV-1 as they amplified segments of the ICP4 and thymidine kinase (TK) genes. As expected, the recombinant vaccine analyzed was negative to the amplification of the studies genes. The amplification of the ICP4 and TK genes in the field samples demonstrated the presence of GaHV-1 in the province, but the possibility that it was a vaccine-derived virus from the use of the recombinant vaccine authorized for use in the study area was ruled out. Since the birds did not present clinical signs related to ILT, it was determined that an outbreak of the disease could not be confirmed. However, a molecular study with full genome sequencing is required to obtain conclusive results. However, the use of CEO-type vaccines should be avoided in vaccination schedules in Tungurahua Province, and only the use of vectorized vaccines authorized by the national regulatory authority should continue.